Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Trending on Bing
Ex-KY officer found guilty
US added just 12,000 jobs
How to vote
Campaigns in Las Vegas
Campaign in Michigan
MrBeast probe findings
To close 140 restaurants
WA activates National Guard
Warhol artworks stolen
PA ballot case ruling
NC early voting record
Peanut the squirrel seized
Iran threatens Israel, US
US bolsters Middle East
Hit with sex abuse charges
World Series celebration
$425M military aid to UKR
Adams returns to court
Orlando mass shooting
To vote on new contract
Soldier charged with murder
Pilot error in F-35 crash
TX citizenship status law
Fire closes Ohio River bridge
School board pres resigns
ACA enrollment opens
Performers announced
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Zepbound, Lilly
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still disappointed
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
Lilly’s Mounjaro, Zepbound drugs see strong demand. So why did sales disappoint?
Eli Lilly’s stock heads for biggest selloff in more than three years after sales of anti-obesity drugs Mounjaro and Zepbound came up well short of forecasts.
Eli Lilly Earnings Have Wall Street Jittery on Zepbound Sales. What Comes Next.
One big idea has loomed over healthcare stocks over the past two years: Demand for the new GLP-1 weight loss medicines from Eli Lilly and Novo Nordisk will be insatiable. That hope has added hundreds of billions of dollars to the market values of Lilly and Novo,
Eli Lilly's Zepbound and Mounjaro are no longer in shortage. Here's where their sales still fell short
Eli Lilly's blockbuster weight loss drug Zepbound and diabetes treatment Mounjaro posted weaker-than-expected sales for the third quarter, even as both medicines have largely recovered from widespread shortages in the U.
10d
on MSN
Lilly's weight loss drug shortage deemed over, but hurdles remain
For many patients on tirzepatide, a transformative medication used for weight loss and diabetes, the end of the drug's ...
2d
Ozempic, Wegovy move closer to no longer being in shortage, FDA says
Both Ozempic and Mounjaro are approved by the FDA to treat Type 2 diabetes, but some doctors prescribe the medication ...
2d
Knockoff weight loss drugs are having a moment. Eli Lilly isn't worried
CEO David Ricks said the sale of cheaper, off-brand versions of the company’s blockbuster weight loss drug isn’t having a ...
4d
on MSN
What You Need To Know Ahead of Eli Lilly's Earnings Wednesday
Eli Lilly will report third-quarter earnings Wednesday morning. Investor focus remains on the production and sales of its ...
2d
on MSN
Eli Lilly stock tumbles after drug giant misses estimates and slashes profit guidance
Skyrocketing demand for weight loss and diabetes drugs has forced Eli Lilly and Novo Nordisk, to invest billions to increase ...
The American Journal of Managed Care
1d
5 Essential Drugs Currently Facing Shortages
US drug shortages have decreased from 323 to 277 as of September 2024, yet many essential drugs remain scarce, with 50% of ...
2d
on MSN
Hims & Hers stock falls 14% after FDA changes semaglutide supply status (update)
Hims & Hers (HIMS) stock fell 14% following news that Novo Nordisk’s (NVO) weight-loss drug Wegovy is no longer ...
2d
on MSN
Novo Nordisk's Ozempic and Wegovy now available in the U.S. after shortages, FDA says
It is a sign that Novo Nordisk’s efforts to ramp up the supply of those drugs are starting to pay off, as demand continues to ...
10d
Shady drugmaker used code words to sell knockoff weight-loss drug: Lawsuit
Amid ongoing legal battles over coveted GLP-1 therapies, a drug vendor in Washington state is accused of running an ...
2d
What You May Have Missed From Eli Lilly's Q3 2024 Earnings Disappointment
LLY’s slashed revenue and earnings guidance for 2024 were a surprise, especially given substantial raises to its outlook ...
Medscape
5d
Battle Continues Over Compounded GLP-1s
Novo Nordisk seeks to put a stop to semaglutide compounding, whereas the FDA agrees to allow compounding of tirzepatide, for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback